Multiple Myeloma Case Developed During the Use of the Teriparatide

Recombinant human parathyroid hormone (1-34) (rhPTH 1-34), teriparatide, is a class of anabolic therapy for treating severe osteoporosis. Although plasma cell dyscrasias are excluded among the known side effects of teriparatide treatment, their association in the form of case reports has been report...

Full description

Bibliographic Details
Published in:Türk Osteoporoz Dergisi
Main Authors: Zehra Erdemir, Ayşe İyiyapıcı Ünübol, Mustafa Ünübol, Esra Ercan Aktekin, İrfan Yavaşoğlu, Engin Güney
Format: Article
Language:English
Published: Turkish Society of Osteoporosis 2022-04-01
Subjects:
osteoporosis
teriparatide
multiple myeloma
Online Access: http://www.turkosteoporozdergisi.org/archives/archive-detail/article-preview/multiple-myeloma-case-developed-during-the-use-of-/51345

Internet

http://www.turkosteoporozdergisi.org/archives/archive-detail/article-preview/multiple-myeloma-case-developed-during-the-use-of-/51345

Similar Items